Modified liposome for drug delivery, use of liposome for drug delivery, especially with anti-cancer activity, and ways to load liposome with drugs, especially with anti-cancer activity

A liposome composed of at least three lipids, including DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine) in an amount of 48.6 to 70.7% by weight, cholesterol in an amount of 18.3 to 18.6% by weight, DSPE-PEG(2000)amine (ammonium salt of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000]) in an amount of 10.6 to 10.7% by weight for use in the transfer of at least one drug, in particular one with anticancer activity.

A method of loading a liposome with drugs, especially with anticancer activity, characterised by the fact that into liposomes composed of at least three lipids, including DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine) in an amount of 48.6 to 70.7% by weight, cholesterol in an amount of 18.3 to 18.6% by weight, DSPE-PEG(2000)amine in an amount of 10.6 to 10.7% by weight, at least one drug is introduced in such a way that the liposomes are dialysed in buffer 0.1 M PBS with a pH of 7.4 to 9.0 from 12 h to 24 h to obtain a pH and concentration gradient, a solution of at least one drug in DMSO or water at a concentration of 50 mg/ml is added sequentially for every 1 ml of liposome solution, the solution is then cooled to 4° C. and allowed to stand from 4 h to 14 h or heated in a water bath for 15 to 60 minutes at 45 to 60° C., after which the resulting nanoparticles are dialysed in PBS buffer pH 7.4 at 4° C. or purified on a chromatography column and the drug concentration and the encapsulation rate of the drug into the liposomes are determined.

A method of loading a liposome with drugs, particularly those having anticancer activity, characterised in that into liposomes composed of at least three lipids, including DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine) in an amount of 48.6 to 70.7% by weight, cholesterol in an amount of 18.3 to 18.6 wt %, DSPE-PEG(2000)amine in an amount of 10.6 to 10.7 wt %, at least one drug is introduced, the primary drug being staurosporine, such that the liposomes are dialysed in 0.1 M acetate buffer pH 4.5 to 5.5 for 2 h to 12 h at 4° C. to replace the external buffer, and then 20 to 50 ul of DMSO for each 1 ml of liposomes and 3.76 ul to 40 ul of staurosporine solution at 40 mg/ml in DMSO are added to the liposomes in divided doses, stirring each time until the precipitate disappears, after which the solution is left at room temperature for 15 to 60 minutes and the excess staurosporine is purified by dialysis in 0.1M PBS buffer, pH 7.4 to 8.5, changing the external buffer three times after 1 h, 6 h and 12 h.